Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Shi, Ming ^a   Sun, Wan Li ^a   Hua, Yan Yan ^a   Han, Bo ^a   Shi, Long ^a  

^a Central Laboratory   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; COVALENTLY CLOSED CIRCULAR DNA; ENTECAVIR; HEPATITIS B(E) ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; CIRCULAR DNA; GUANINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CHINESE; CHRONIC DISEASE; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SEROCONVERSION; TREATMENT DURATION; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; LIVER; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

HEPATITIS B VIRUS;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DNA, CIRCULAR; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84922362557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117741     Document Type: Article

References (24)

1. Lai CL, Ratziu V, Yuen MF, Poynard T (2003). Viral hepatitis B. Lancet, 362:2089-94. PMID: 14697813
2. Seeger C, MasonWS (2000). Hepatitis B virus biology.Microbiol Mol Biol Rev, 64:51-68. PMID: 10704474
3. Tuttleman JS, Pourcel C, Summers J (1986). Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell, 47:451-60. PMID: 3768961
4. Caruntu FA, Molagic V (2005). CccDNA persistence during natural evolution of chronic VHB infection. Rom J Gastroenterol, 14:373-7. PMID: 16400354
5. He ML, Wu J, Chen Y, Lin MC, Lau GK, et al. (2002). A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophys Res Commun, 295:1102-7. PMID: 12135608
6. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, et al (2004). Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 126:1750-8. PMID: 15188170
7. Chen Y, Sze J, He ML (2004). HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J Gastroenterol, 10:82-5. PMID: 14695774
8. Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, et al (2004). Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology, 40:727-37. PMID: 15349913
9. Yuen MF, Wong DK, Sum SS, Yuan HJ, Yuen JC, et al (2005). Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol, 100:1099-103. PMID: 15842584
10. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, et al (2006). Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology, 44:675-84. PMID: 16941693
11. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, et al. (1997). Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol, 71:9392-9. PMID: 9371599
12. Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J (1985). Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology, 5:728-34. PMID: 4029888
13. Chen Y, Sze J, He ML (2004). HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J Gastroenterol, 10:82-5. PMID: 14695774
14. Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, et al (2007). Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat, 14:55-63. PMID: 17212645
15. Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V, Denis F, Alain S (2006). Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods, 138:70-9. PMID: 16962180
16. Su Q, Wang SF, Chang TE, Breitkreutz R, Henning H, et al (2001). Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res, 7:2005-15. PMID: 11448918
17. Zhang W, Hacker HJ, Tokus M, Bock T, Schroder CH (2003). Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol, 71:24-30. PMID: 12858405
18. Breitkreutz R, Zhang W, Lee M, HoffmannA, TokusM, et al (2001). Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HBs carriers with hepatocellular carcinoma. Ann N Y Acad Sci, 945:195-206. PMID: 11708479
19. Loustaud-Ratti V, Wagner A, Carrier P, Marczuk V, Chemin I, et al (2013). Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg- patients coinfected or not with HIV or HCV. Clin Res Hepatol Gas, 37: 373-383. doi: 10.1016/j.clinre.2012.11.002 PMID: 23477988
20. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL (2006). One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther, 11:909-16. PMID: 17302253
21. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, et al (2003). CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 77:68-76. PMID: 12477811
22. Zhou T, Guo JT, Nunes FA, Molnar-Kimber KL, Wilson JM, et al (2000). Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections. J Virol, 74:11754-63. PMID: 11090175
23. Shi M, Wang RS, Zhang H, Zhu YF, Han B, et al (2006). Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother, 58:1031-5. PMID: 16987866
24. Hagiwara S, Kudo M, Osaki Y, Takita M, Inoue T, et al (2013). Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol, 85: 987-995. doi: 10.1002/jmv.23564 PMID: 23588724